American journal of preventive cardiology · 2025
Association between proprotein convertase subtilisin/kexin type 9 targeted therapies and the risk of arrhythmias: a meta-analysis of randomized controlled trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jaiswal Vikash, Goyal Aman, Deb Novonil, Shama Nishat, Mittal Vivek, Rajak Kripa, Halder Anupam, Khadka Sulochana, Kumar Tushar, Ahmed Raheel, Bytyçi Ibadete, Banach Maciej, Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group
Аннотация
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) targeted therapies effectively lower low-density lipoprotein cholesterol (LDL-C) and circulating PCSK9 levels. However, their effect on the risk of arrhythmias remains uncertain, and this meta-analysis aims to investigate the association.
METHODS: We performed a systematic literature search on all electronic databases for relevant randomized controlled trials (RCTs) from inception until 16th August 2024. Primary clinical endpoint was atrial fibrillation (AFib), while the secondary endpoints were atrial flutter (AFL), ventricular fibrillation (VF), ventricular tachycardia (VT), supraventricular tachycardia (SVT), sudden cardiac death (SCD), cardiac arrest and atrioventricular blocks.
RESULTS: 28 RCTs with 95,520 patients were finally included in the analysis. The mean age of the group treated with PCSK9 inhibitors was similar to the control group (60.13 years vs. 60.06 years). At mean follow-up of 1.6 years the PCSK9i group had similar risk of AFib (OR, 0.88; 95 %CI: 0.75-1.03, p = 0.11), AFL (OR, 1.04; 95 %CI: 0.70-1.54, p = 0.84), VT (OR, 0.80; 95 %CI: 0.58-1.11, p = 0.18), VF (OR, 0.77;95 %CI: 0.40-1.47, p = 0.43) and SVT (OR, 0.94; 95 %CI: 0.56-1.58, p = 0.82) compared to control group. Similarly, the SCD (OR, 0.91; 95 %CI: 0.62-1.32, p = 0.61), and AV block (OR, 0.72; 95 %CI: 0.34-1.52, p = 0.39) did not differ between the groups.
CONCLUSION: This meta-analysis did not find a significant association between PCSK9i and arrhythmias.
METHODS: We performed a systematic literature search on all electronic databases for relevant randomized controlled trials (RCTs) from inception until 16th August 2024. Primary clinical endpoint was atrial fibrillation (AFib), while the secondary endpoints were atrial flutter (AFL), ventricular fibrillation (VF), ventricular tachycardia (VT), supraventricular tachycardia (SVT), sudden cardiac death (SCD), cardiac arrest and atrioventricular blocks.
RESULTS: 28 RCTs with 95,520 patients were finally included in the analysis. The mean age of the group treated with PCSK9 inhibitors was similar to the control group (60.13 years vs. 60.06 years). At mean follow-up of 1.6 years the PCSK9i group had similar risk of AFib (OR, 0.88; 95 %CI: 0.75-1.03, p = 0.11), AFL (OR, 1.04; 95 %CI: 0.70-1.54, p = 0.84), VT (OR, 0.80; 95 %CI: 0.58-1.11, p = 0.18), VF (OR, 0.77;95 %CI: 0.40-1.47, p = 0.43) and SVT (OR, 0.94; 95 %CI: 0.56-1.58, p = 0.82) compared to control group. Similarly, the SCD (OR, 0.91; 95 %CI: 0.62-1.32, p = 0.61), and AV block (OR, 0.72; 95 %CI: 0.34-1.52, p = 0.39) did not differ between the groups.
CONCLUSION: This meta-analysis did not find a significant association between PCSK9i and arrhythmias.